Allogene Therapeutics (ALLO) Equity Average (2018 - 2026)

Allogene Therapeutics' Equity Average history runs 9 years deep, the most recent figure standing at $285.7 million for Q1 2026.

• In Q1 2026, Equity Average fell 29.24% year-over-year to $285.7 million; the TTM figure through Mar 2026 stood at $285.7 million (down 29.24% YoY), while the FY2025 annual figure was $357.4 million, down 23.51% from the prior year.
• Equity Average came in at $285.7 million for Q1 2026 at Allogene Therapeutics, down from $303.9 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $895.2 million in Q1 2022 to a low of $285.7 million in Q1 2026.
• A 5-year average of $540.6 million and a median of $489.4 million in 2024 frame the typical range for Equity Average.
• Across the five-year window, Equity Average dropped 14.05% in 2022 and tumbled 32.58% in 2025, its largest moves.
• Allogene Therapeutics' Equity Average stood at $705.1 million in 2022, then decreased by 22.51% to $546.4 million in 2023, then declined by 18.94% to $443.0 million in 2024, then plunged by 31.39% to $303.9 million in 2025, then fell by 6.0% to $285.7 million in 2026.
• According to Business Quant data, Equity Average over the past three periods registered $285.7 million, $303.9 million, and $329.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison